Two different problems, two different injections

Patients researching ChondroFiller and Arthrosamid often arrive at the same question: which one is better for a damaged knee? The honest answer is that 'better' is the wrong frame. These two injections do not compete for the same indication — they treat anatomically separate structures, and the correct one for any given patient is almost always determined by their imaging findings, not by a preference ranking.

ChondroFiller is placed at the cartilage surface on the load-bearing bone ends. Arthrosamid integrates into the synovial membrane — the soft tissue lining the joint — where it forms a durable cushioning layer. Because they act on different anatomy, the decision between them is a pathology-match exercise: what does this particular knee actually have?

It is also worth stating clearly that no head-to-head controlled trial comparing the two has been conducted. Any claim that one is categorically superior to the other should be treated with caution. Both are delivered as ultrasound-guided outpatient injections; neither is a surgical procedure.

The sections that follow cover how each injection works, which patients typically suit each one, and what options exist when both problems are present in the same joint.

How ChondroFiller works on a cartilage defect

ChondroFiller is a CE-marked Class III medical device — an acellular type I collagen gel, delivered as an ultrasound-guided injection directly into a cartilage defect. At body temperature it sets within a few minutes, forming a three-dimensional scaffold that physically fills the damaged area.

The mechanism is acellular matrix-induced chondrogenesis. Rather than introducing donor cells, the scaffold creates a structure that the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — migrate into and use as a framework to promote endogenous repair. A 2025 ex vivo study provided direct evidence of this process, measuring a 2.4-fold increase in DNA content within the scaffold by day 14, confirming meaningful cellular migration in that timeframe. Over one to two years the collagen matrix is progressively resorbed, ideally replaced by the patient's own repair tissue.

In published knee studies, patients with suitable defects showed International Knee Documentation Committee (IKDC) score improvements of approximately 30 points at 12 months — a clinically meaningful gain on a validated outcome measure. A 2025 peer-reviewed study in wrist cartilage defects (Demmer et al.) found significantly superior cartilage quality scores versus untreated controls at follow-up arthroscopy (Outerbridge median 1.5 versus 3, P=0.006), adding biological weight to the functional data.

Eligibility is specific. ChondroFiller suits focal, contained, full-thickness defects — typically under 2 cm² — in a joint whose architecture is otherwise largely intact. Patients with advanced, widespread osteoarthritis tend to see less benefit, because the regenerative environment that the scaffold depends on is compromised when degeneration is diffuse rather than discrete.

How Arthrosamid works on a worn knee joint

Arthrosamid works on a different structure entirely. Rather than filling or repairing the cartilage surface, this 2.5% polyacrylamide hydrogel — 97.5% water by composition — integrates into the synovial membrane, the soft tissue that lines the inside of the joint capsule. Once embedded, it forms a permanent sub-synovial cushion that reduces the mechanical load transmitted through the joint and damps the inflammatory signalling associated with established osteoarthritis.

The injection is a single 6 mL intra-articular dose. Relief does not arrive immediately; integration takes time, and most patients notice meaningful improvement somewhere between two and twelve weeks after the procedure. Because the hydrogel is non-biodegradable, it is not absorbed or broken down — there is no planned repeat injection cycle of the kind that hyaluronic acid viscosupplementation typically requires.

The clinical follow-up dataset behind Arthrosamid is unusually long for an injectable product. Prospective studies by Bliddal and colleagues tracked outcomes at 6 months, 12 months, 2 years (OARSI 2022), and 3 years (OARSI 2023), each reporting statistically significant, sustained pain reduction. At WCO 2025, five-year efficacy data and ten-year safety data were presented, with no significant long-term complications identified across the cohort.

The permanence of the hydrogel is worth understanding in both directions. For patients who respond well, it avoids the burden of repeat treatments. For those considering the injection, it means the material remains in the joint indefinitely — a factor a consultant will discuss at assessment, alongside the gradual onset and realistic expectations for pain reduction rather than structural cartilage repair.

Which injection matches your diagnosis

The dividing line, in practice, comes down to defect geometry and disease pattern — both of which require imaging to establish reliably.

A focal, full-thickness cartilage lesion within a joint that is otherwise structurally sound is the profile that directs a consultant toward ChondroFiller. The scaffold's mechanism depends on the right environment: viable surrounding tissue, intact subchondral bone, and progenitor cells capable of migrating into the matrix. That environment exists in a joint with contained, discrete damage.

Where cartilage loss is diffuse — spread across the joint surface and graded Kellgren–Lawrence II to IV — Arthrosamid addresses the problem more directly. The goal at that stage is durable load cushioning and inflammation reduction across a joint that has lost structural integrity in multiple areas, not targeted repair of a single site.

What a consultant will be assessing

Weight-bearing X-rays establish Kellgren–Lawrence grade and joint space narrowing. MRI characterises defect depth, size, and location. Neither can be replaced by symptoms alone: pain does not reliably distinguish a focal lesion from generalised wear, and ChondroFiller outcomes decline in advanced OA (KL III/IV) — which is precisely why imaging drives eligibility rather than patient preference.

Age, body weight, activity level, and limb alignment all contribute to the recommendation. A knee carrying significant varus or valgus load may need that mechanical factor addressed alongside whichever injection is selected, or the benefits of either will be partially offset by the forces continuing to act on the joint.

When both injections are used together

For some patients, the imaging picture does not present a clean either/or decision. A focal cartilage defect can coexist with broader synovial inflammation — meaning neither injection alone covers both problems. It is this patient profile that the CFI+ protocol is designed for.

CFI+ delivers ChondroFiller onto the cartilage surface and Arthrosamid into the synovial lining in a single outpatient appointment. The two products are working through entirely different mechanisms and should not be described as a combined filler or a single joint-padding treatment. ChondroFiller is the regenerative scaffold component — recruiting the patient's own cells to address the structural defect. Arthrosamid is the mechanical cushioning component — integrating into the synovium to reduce load and damp inflammation across the joint more broadly. Each injection has its own target, its own mode of action, and its own expected timeline for effect.

Combination treatment is not routine for every patient. Eligibility depends on what the weight-bearing X-rays and MRI show, and on whether both pathologies are meaningfully present rather than incidental. A consultant assessment is the only reliable way to determine whether a combined approach is appropriate for a specific individual.

For London-based patients, the CFI+ protocol is available through the London Cartilage Clinic; guide costs are confirmed at consultation. Clinicians working within the wider MSK Doctors network can carry out the same structured imaging assessment and advise on pathway options for patients outside London.

Getting the right assessment at MSK Doctors

Deciding between these two pathways — or identifying that both are needed — requires imaging and a consultant review, not a symptom description alone. Weight-bearing X-rays and MRI are the minimum to establish defect geometry, Kellgren–Lawrence grade, and joint-space profile before any recommendation is made.

MSK Doctors consultants carry out exactly this assessment at the group's clinics in Sleaford and Grantham, Lincolnshire. No GP referral is needed to book, and appointments are not subject to NHS waiting lists. The Sleaford site has an Open MRI scanner on-site, which allows imaging to be completed and reviewed in the same clinical setting rather than at a separate hospital department — a practical benefit when the imaging findings directly shape what is discussed in the consultation.

The group holds CQC registration and a 'Good' rating across all five inspection domains. Patients from across Lincolnshire and the wider East Midlands catchment are seen regularly. To arrange a consultant assessment, visit mskdoctors.com.